NVO

Novo Nordisk A/S

Add to Watchlist

Advanced Chart

67.740

+1.970(+3.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

67.750

Open

64.090

VWAP

66.22

Vol

18.22M

Mkt Cap

227.88B

Low

64.020

Amount

1.21B

EV/EBITDA(TTM)

13.27

Total Shares

4.45B

2.06T

EV/OCF(TTM)

15.70

P/S(TTM)

6.53

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

93.32B

+8.91%

84.12B

+17.96%

78.38B

+15.16%

Estimates Revision

The market is revising Downward the revenue expectations for Novo Nordisk A/S (NVO) for FY2025, with the revenue forecasts being adjusted by -3.29% over the past three months. During the same period, the stock price has changed by -17.18%.

Revenue Estimates for FY2025

Revise Downward

-3.29%

In Past 3 Month

Stock Price

Go Down

-17.18%

In Past 3 Month

9 Analyst Rating

22.82% Upside

Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 83.20 USD with a low forecast of 61.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

5 Hold

1 Sell

Hold

22.82% Upside

Current: 67.740

Low

61.00

Averages

83.20

High

102.00

22.82% Upside

Current: 67.740

Low

61.00

Averages

83.20

High

102.00

BMO Capital

Evan David Seigerman

Buy

Hold

Downgrades

$105 → $64

2025-04-17

Reason

BMO Capital

Evan David Seigerman

Price Target

$105 → $64

2025-04-17

Downgrades

Buy

Hold

Reason

BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company's obesity competitor Eli Lilly (LLY) has made sizable advancements in its commercial and clinical portfolio, causing it to overtake Novo's early lead, the analyst tells investors in a research note. The firm says updates from Lilly's oral GLP1, orforglipron, are likely to pressure Novo shares, which will only be compounded by what it expects to be "softer" Q1 results. BMO is moving to the sidelines until Novo can demonstrate clinical and commercial "prowess."

UBS

Jo Walton

Strong Sell

Strong Buy

Upgrades

n/a

2025-01-08

Reason

UBS

Jo Walton

Price Target

n/a

2025-01-08

Upgrades

Strong Sell

Strong Buy

Reason

UBS analyst upgraded Novo Nordisk to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is "well placed" to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still a higher efficacy treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an attractive entry point following the "overdone" selloff.

BMO Capital

Evan David Seigerman

Buy

Maintains

$156 → $105

2024-12-23

Reason

BMO Capital

Evan David Seigerman

Price Target

$156 → $105

2024-12-23

Maintains

Buy

Reason

BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema's Phase 3 data readout failed to meet investor expectations. CagriSema was supposed to best Eli Lilly's (LLY) Zepbound, but missed the mark on efficacy and tolerability, which "cuts the margin of error for execution in 2025," so Q4 results "cannot miss and the 2025 guide must be strong," the analyst tells investors. Given the data, the firm is cutting its Novo price target, but thinks the reaction in shares today has been "overdone," the analyst added.

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

$160

2024-11-06

Reason

Cantor Fitzgerald

Louise Chen

Price Target

$160

2024-11-06

Reiterates

Buy

Reason

BMO Capital

Evan David Seigerman

Buy

Maintains

$160 → $156

2024-10-17

Reason

BMO Capital

Evan David Seigerman

Price Target

$160 → $156

2024-10-17

Maintains

Buy

Reason

BMO Capital analyst Evan Seigerman lowered the firm's price target on Novo Nordisk to $156 from $160 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. Looking at script growth for Ozempic and Wegovy from Q2, the firm sees 4% and 24% growth, respectively, but while growth continues to be impressive, sell-side estimates may now be catching up to this growth, the analyst tells investors in a research note. Novo's Victoza scripts have declined nearly 50% from Q2 however as patients and providers transition to more efficacious agents Mounjaro / Ozempic, the firm added.

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

$160

2024-10-10

Reason

Cantor Fitzgerald

Louise Chen

Price Target

$160

2024-10-10

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Novo Nordisk A/S (NVO.N) is 16.61, compared to its 5-year average forward P/E of 28.65. For a more detailed relative valuation and DCF analysis to assess Novo Nordisk A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

28.65

Current PE

16.61

Overvalued PE

34.02

Undervalued PE

23.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

20.44

Current EV/EBITDA

12.39

Overvalued EV/EBITDA

24.18

Undervalued EV/EBITDA

16.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

9.79

Current PS

5.67

Overvalued PS

11.73

Undervalued PS

7.85

Financials

Annual

Quarterly

FY2025Q1

YoY :

+15.63%

11.01B

Total Revenue

FY2025Q1

YoY :

+17.87%

5.47B

Operating Profit

FY2025Q1

YoY :

+10.58%

4.09B

Net Income after Tax

FY2025Q1

YoY :

+10.84%

0.92

EPS - Diluted

FY2025Q1

YoY :

+82.49%

1.41B

Free Cash Flow

FY2025Q1

YoY :

-1.58%

83.49

Gross Profit Margin - %

FY2025Q1

YoY :

+19.45%

24.63

FCF Margin - %

FY2025Q1

YoY :

-4.37%

37.18

Net Margin - %

FY2025Q1

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 764.45% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

9.8M

Volume

6-9

Months

0.0

Volume

0-12

Months

1.1M

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.3M

Volume

Months

6-9

0.0

Volume

Months

0-12

4.3M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

16.0K

USD

3-6

Months

0.0

USD

6-9

Months

83.0K

USD

0-12

Months

0.0

USD

Bought

0-3

40.5K

USD

Months

3-6

0.0

USD

Months

6-9

32.5K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

NVO News & Events

Events Timeline

2025-05-12 (ET)

2025-05-12

10:59:57

White House publishes Trump executive order aimed at lowering drug prices

2025-05-12

06:16:19

Many patients soon to be forced to switch obesity drug, NYT says

2025-05-07 (ET)

2025-05-07

09:30:10

Novo Nordisk CFO skeptical Trump EO can cut production timelines, Reuters says

News

9.0

13:24 PMBenzinga

PinnedNovo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

9.0

09:00 AMNASDAQ.COM

PinnedNovo Nordisk's Sogroya Shows Tolerability In Children With Growth Disorders

6.5

17:39 PMCNBC

Jim Cramer says investors shouldn't chase Monday's market rally — here's why

People Also Watch

Aeva Technologies Inc

ATAI Life Sciences NV

DiaMedica Therapeutics Inc

Transcontinental Realty Investors Inc

Gorilla Technology Group Inc

Lifecore Biomedical Inc

Helix Acquisition Corp II

FAQ

What is Novo Nordisk A/S (NVO) stock price today?

The current price of NVO is 67.74 USD — it has increased 3 % in the last trading day.

NVO

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

NVO News & Events

Events Timeline

News

People Also Watch

FAQ

What is Novo Nordisk A/S (NVO) stock price today?

What is Novo Nordisk A/S (NVO)'s business?

What is the price predicton of NVO Stock?

What is Novo Nordisk A/S (NVO)'s revenue for the last quarter?

What is Novo Nordisk A/S (NVO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Novo Nordisk A/S (NVO)'s fundamentals?

How many employees does Novo Nordisk A/S (NVO). have?

What is Novo Nordisk A/S (NVO) market cap?